EAC

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Retrieved on: 
수요일, 5월 29, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Patient, Progression-free survival, Mesothelioma, Renal cell carcinoma, Neck, ESCC, Risk, Colorectal cancer, Recurrence, Lung cancer, BMY, PFS, Netherlands Cancer Institute, Head, Cisplatin, NSCLC, Cancer, EAC, Congress, GEJ, Civil service commission, European Commission, HR, Death, Melanoma, PR, ESMO, Jan-Arie van der Heijden, European, Checkmate, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).
  • With this approval, Opdivo in combination with cisplatin and gemcitabine becomes the first concurrent immunotherapy-chemotherapy approved for the treatment of adult patients with unresectable or metastatic UC in the first-line setting in the European Union.
  • “With today’s approval by the EC, we’re pleased to be able to offer Opdivo concurrently with chemotherapy to eligible patients with unresectable or metastatic UC,” said Dana Walker, M.D., M.S.C.E., vice president and global program lead, gastrointestinal and genitourinary cancers, Bristol Myers Squibb.
  • “This is a major step forward for this patient population and reinforces our goal of advancing and delivering new options to patients with difficult-to-treat cancers.

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

Retrieved on: 
화요일, 5월 28, 2024
Patient, American Academy, PD, Asthma, Immunology, FDA, Therapy, Adrenaline, Allergy, Conference, EAC, Pharmacokinetics, Anaphylaxis, American College, Pharmaceutical industry

WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented at the Eastern Allergy Conference (EAC).

Key Points: 
  • WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented at the Eastern Allergy Conference (EAC).
  • Taking place from May 30 through June 2, 2024, in Palm Beach, Florida, EAC features the most current information from the field's top experts on Allergy, Asthma and Immunology.
  • Anaphylm is the Company’s first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
  • “Anaphylm has the potential to transform the treatment of severe allergic reactions, including anaphylaxis.

Terran Orbital Reports First Quarter 2024 Financial Results

Retrieved on: 
화요일, 5월 14, 2024
Technology, Professional Services, Science, Engineering, Satellite, Research, Other Defense, Aerospace, Telecommunications, Contracts, Manufacturing, Software, Networks, Defense, Internet, Mobile, Wireless, Finance, Partnership, Capital expenditure, Lockheed Martin, EAC, Capital, PIPE, Depreciation, GAAP, Orbital Corporation, Hand, Lockheed, Entrepreneurship, Disclosure, Video game

Terran Orbital Corporation (NYSE: LLAP) ("Terran Orbital" or the "Company"), a leading manufacturer of satellite products primarily serving the aerospace and defense industries, today announced financial results and operational highlights for the three months ended March 31, 2024.

Key Points: 
  • Terran Orbital Corporation (NYSE: LLAP) ("Terran Orbital" or the "Company"), a leading manufacturer of satellite products primarily serving the aerospace and defense industries, today announced financial results and operational highlights for the three months ended March 31, 2024.
  • Commenting on the first quarter, Mr. Bell said, “We expect the delayed revenue from this single program to be recognized by the end of the third quarter of 2024.
  • Adjusted EBITDA(1) was $(28.2) million for the first quarter of 2024, compared to $(22.6) million for the same quarter in 2023.
  • As of March 31, 2024, Terran Orbital had $43.7 million of cash on hand and approximately $316.7 million in gross debt obligations.

Vecima and VECTOR TECH SOLUTIONS Secure Entra® DAA Launching Point with ASTA-NET in Poland

Retrieved on: 
목요일, 5월 9, 2024
Technology, Audio, Video, Telecommunications, 5G, Networks, Internet, Carriers and Services, DAA, Ecosystem, ICT, TSX, Partnership, PHY, VCM, Vecima Networks, Senior, EAC, Multimedia, Architecture, RMD, Internet service provider

Vecima Networks Inc. (TSX: VCM) today announced that VECTOR TECH SOLUTIONS is deploying Vecima’s Entra® SC-1D Access Node and Entra® Access Controller (EAC) solutions for ASTA-NET, a telecommunications provider in Poland.

Key Points: 
  • Vecima Networks Inc. (TSX: VCM) today announced that VECTOR TECH SOLUTIONS is deploying Vecima’s Entra® SC-1D Access Node and Entra® Access Controller (EAC) solutions for ASTA-NET, a telecommunications provider in Poland.
  • View the full release here: https://www.businesswire.com/news/home/20240509796116/en/
    The collaboration underscores Vecima’s commitment to expanding its footprint in the European market, with VECTOR TECH SOLUTIONS providing local expertise as a Vecima reseller in Poland.
  • ASTA-NET’s adoption of Vecima’s technology through VECTOR TECH SOLUTIONS represents a pivotal step in enhancing its network infrastructure to deliver superior broadband services.
  • “Collaboration with global broadband technology providers such as Vecima is a great honor,” said Artur Salwach, Sales Managing Director at VECTOR TECH SOLUTIONS.

CFEX Selected as Finalist for the EDF Pulse Awards

Retrieved on: 
화요일, 5월 7, 2024
Other Energy, Software, Environment, Alternative Energy, Energy, Environmental Issues, Technology, Green Technology, American Council, Transport, Amazon, Allen County, Indiana, GHG, EAC, PPA, Pulse, Renewable energy

CFEX, Inc. announced today that it has been selected as one of the finalists for the EDF Pulse Awards, a strong validation of the company’s technology and its holistic approach to streamline and automate the end-to-end business processes for decarbonization of energy-related emissions.

Key Points: 
  • CFEX, Inc. announced today that it has been selected as one of the finalists for the EDF Pulse Awards, a strong validation of the company’s technology and its holistic approach to streamline and automate the end-to-end business processes for decarbonization of energy-related emissions.
  • EDF’s selection of CFEX as one of the finalists for this year’s Pulse Awards is the latest in a series of innovation awards that the company has received, preceded by Amazon , the American Council on Renewable Energy (ACORE) , and the Semiconductor Climate Consortium .
  • CFEX has developed a comprehensive suite of applications to track and transact EACs from issuances to purchases and allocation to retirements.
  • By automating these otherwise manual processes, CFEX minimizes transaction costs, errors, and disputes between buyers and sellers; and increases transaction accuracy, efficiency and auditability.

Win a Rivian R1 Series Premium Electric Vehicle! Drawing on July 13, 2024

Retrieved on: 
수요일, 5월 1, 2024
EAC, FAQ, SUV, ESB, WNC, Transport, Environmental Action, IRA, Rivian R1T, Carbon, Policy, Inflation, Renewable energy

WAYNESVILLE, N.C., May 1, 2024 /PRNewswire-PRWeb/ -- EV RAFFLE HAS LAUNCHED!

Key Points: 
  • Drawing to be held at 7pm EDT on July 13, 2024.
  • *Your odds of winning your customizable Rivian R1T (truck) or R1S (SUV) are excellent.
  • Your $200 ticket purchase supports our work to eliminate carbon emissions and deploy renewable energy at scale.
  • Once a winner is randomly selected on July 13, EAC will contact you to determine your preferred build and specifications.

ProPhase Labs Unveils Project ZenQ-AI

Retrieved on: 
화요일, 4월 16, 2024
Project, Cancer, Genomics, Whole genome sequencing, Safety, AI, Esophageal cancer, Nebula Genomics, Genetics, Machine learning, WGS, Doctor of Philosophy, DNA, SNP, Therapy, ADC, Marker beacon, Prophase, NVIDIA, Genome, EAC, Database, Diagnosis, CIO, Biomarker, Algorithm, Spacecraft, Medical device

Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual’s entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company’s BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.

Key Points: 
  • Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI.
  • "The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs.
  • To support the computational demands of Project ZenQ-AI, ProPhase Labs is utilizing a dual-approach in technology.
  • ProPhase Labs invites collaboration from across the scientific and medical communities to join in this groundbreaking initiative.

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

Retrieved on: 
수요일, 4월 10, 2024
Mayo Clinic, Cancer, Genomics, Hospital, Esophageal cancer, Proteomics, Insurance, Partnership, Doctor of Philosophy, Documentation, Clinical professor, Patient, CPT, Prophase, Endoscopy, EAC, Health, GERD, Risk assessment, Medical imaging

Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.

Key Points: 
  • Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.
  • Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future.
  • ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics.
  • Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies.

Lightbridge Senior Executives Assume Key Positions in Prestigious Nuclear Energy Industry Groups

Retrieved on: 
목요일, 3월 21, 2024
Program management, Conference, Growth, EAC, ANS, International Council, IAEA, Nuclear energy, LTBR, Safety, Conference of the parties, Summit

RESTON, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced the appointments of senior Lightbridge executives within leading U.S. nuclear energy industry groups.

Key Points: 
  • RESTON, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced the appointments of senior Lightbridge executives within leading U.S. nuclear energy industry groups.
  • Seth Grae, President and CEO of Lightbridge, has been appointed as the Chair of the American Nuclear Society’s (ANS) International Council.
  • Through educational programs, industry insights, and market intelligence, USNIC facilitates collaboration between legislators across political lines, promoting nuclear energy as a key component of a successful clean energy paradigm.
  • Mr. Grae discussed the growth and future prospects of nuclear power on the eve of the first-ever Nuclear Energy Summit in Brussels.

Terran Orbital Reports Record 2023 Financial Results

Retrieved on: 
월요일, 4월 1, 2024
Technology, Research, Other Defense, Contracts, Engineering, Homeland Security, Aerospace, Manufacturing, Public Policy, Government, Mobile, Wireless, Defense, Construction & Property, Venture Capital, Finance, Satellite, Interior Design, Professional Services, Telecommunications, Software, Networks, Science, Growth, TVAC, Entrepreneurship, Business, Accounting, Capital expenditure, EAC, Orbital Corporation, Capital, Business intelligence, Small business, PIPE, Depreciation, GAAP, Intelligence, Hand

Terran Orbital Corporation (NYSE: LLAP) ("Terran Orbital" or the "Company"), a leading manufacturer of satellite products primarily serving the aerospace and defense industries, today announced financial results and operational highlights for the three and twelve months ended December 31, 2023.

Key Points: 
  • Terran Orbital Corporation (NYSE: LLAP) ("Terran Orbital" or the "Company"), a leading manufacturer of satellite products primarily serving the aerospace and defense industries, today announced financial results and operational highlights for the three and twelve months ended December 31, 2023.
  • Marc Bell, Co-Founder, Chairman, and Chief Executive Officer of Terran Orbital said, “I am pleased to report our company’s strong results for 2023.
  • The future of space is responsive, and Terran Orbital is well-positioned to capitalize on this growing market segment.
  • As of December 31, 2023, Terran Orbital had $71.7 million of cash on hand and approximately $313.8 million in gross debt obligations.